Cantor Fitzgerald Reiterates Overweight Rating on Avidity Biosciences (RNA)
Tweet Send to a Friend
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating and $96.00 price target on vidity Biosciences Inc. (NASDAQ: RNA).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
